Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Kimball

Showing results (121-130 of 230) with videos related to

Pageof 23
Sort By:
Journal of Drugs in Dermatology : JDD|July 11, 2013
A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgarisMa Beatrice Alora Palli, Claire Marie Reyes-Habito, Xinaida T Lima, et al.
Plastic and Reconstructive Surgery|February 23, 2021
Plastic Surgical Management of Hidradenitis SuppurativaErin M Taylor, Ryoko Hamaguchi, Kimberly M Kramer, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentationMolly Wanner, Neil Houston, Emilia Javorsky, et al.
Nature Reviews. Disease Primers|March 14, 2020
Hidradenitis suppurativaRobert Sabat, Gregor B E Jemec, Łukasz Matusiak, et al.
International Journal of Women'S Dermatology|June 10, 2024
Data wobbles in hidradenitis suppurativa clinical trials and potential contributing factors: a retrospective reviewCorey L Snyder, Ruby S Gibson, Stella X Chen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 11, 2025
Cumulative life course impairment: Evidence for hidradenitis suppurativaManeli Doroudian Tehrani, Ruby S Gibson, Corey L Snyder, et al.
JAMA Dermatology|May 8, 2024
Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving AdalimumabSimon J Gunter, Zachary E Holcomb, Barbara D Lam, et al.
Journal of the American Academy of Dermatology|June 12, 2020
Psoriasis: Knowledge, attitudes and perceptions among primary care providersSandeep Kumar, Kelsey Flood, Nicole M Golbari, et al.
Archives of Dermatology|February 20, 2008
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Journal of the American Academy of Dermatology|December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Pageof 23

Showing results (121-130 of 230) with videos related to

Sort By:
Pageof 23
Journal of Drugs in Dermatology : JDD|July 11, 2013
A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgarisMa Beatrice Alora Palli, Claire Marie Reyes-Habito, Xinaida T Lima, et al.
Plastic and Reconstructive Surgery|February 23, 2021
Plastic Surgical Management of Hidradenitis SuppurativaErin M Taylor, Ryoko Hamaguchi, Kimberly M Kramer, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentationMolly Wanner, Neil Houston, Emilia Javorsky, et al.
Nature Reviews. Disease Primers|March 14, 2020
Hidradenitis suppurativaRobert Sabat, Gregor B E Jemec, Łukasz Matusiak, et al.
International Journal of Women'S Dermatology|June 10, 2024
Data wobbles in hidradenitis suppurativa clinical trials and potential contributing factors: a retrospective reviewCorey L Snyder, Ruby S Gibson, Stella X Chen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 11, 2025
Cumulative life course impairment: Evidence for hidradenitis suppurativaManeli Doroudian Tehrani, Ruby S Gibson, Corey L Snyder, et al.
JAMA Dermatology|May 8, 2024
Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving AdalimumabSimon J Gunter, Zachary E Holcomb, Barbara D Lam, et al.
Journal of the American Academy of Dermatology|June 12, 2020
Psoriasis: Knowledge, attitudes and perceptions among primary care providersSandeep Kumar, Kelsey Flood, Nicole M Golbari, et al.
Archives of Dermatology|February 20, 2008
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Journal of the American Academy of Dermatology|December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Pageof 23